UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and Crohn's disease; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy. Its product pipeline includes Evenity for the treatment of osteoporosis; bimekizumab for psoriasis, psoriatic arthritis, and ankylosing spondylitis diseases; dapirolizumab pegol for systemic lupus erythematosus; padsevonil for highly drug resistant epilepsy; seletalisib for Sjögren's syndrome; rozanolixizumab for immune thrombocytopenia; UCB4144/VR942 for asthma; UCB6673, UCB7858, and UCB0159 for the treatment of neurology; and UCB3491 and UCB0599 for bone treatment. The company has a collaboration agreement with Enable Injections, Inc. UCB SA was founded in 1928 and is based in Brussels, Belgium.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone32-2559-9999
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.55 billion
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
UCB (OTCMKTS:UCBJF) Frequently Asked Questions
What is UCB's stock symbol?
UCB trades on the OTCMKTS under the ticker symbol "UCBJF."
What is the consensus analysts' recommendation for UCB?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for UCB.
Has UCB been receiving favorable news coverage?
News stories about UCBJF stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. UCB earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of UCB's key competitors?
Some companies that are related to UCB include Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Allergan (AGN), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF) and Merck KGaA (MKGAF).
Who are UCB's key executives?
UCB's management team includes the folowing people:
- Mr. Jean-Christophe Tellier, Chief Exec. Officer and Exec. Director (Age 60)
- Mr. Detlef Thielgen, CFO & Exec. VP (Age 59)
- Mr. Charl Van Zyl, COO & Exec. VP (Age 52)
- Dr. Bharat Tewarie, Chief Marketing Officer & Exec. VP (Age 58)
- Prof. Iris Löw-Friedrich, Chief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VP (Age 59)
How do I buy shares of UCB?
Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is UCB's stock price today?
One share of UCBJF stock can currently be purchased for approximately $88.67.
How big of a company is UCB?
UCB has a market capitalization of $17.25 billion and generates $4.55 billion in revenue each year.
What is UCB's official website?
How can I contact UCB?
UCB's mailing address is 60 ALLEE DE LA RECHERCHE, BRUSSELS C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected]
MarketBeat Community Rating for UCB (OTCMKTS UCBJF)
MarketBeat's community ratings are surveys of what our community members think about UCB and other stocks. Vote "Outperform" if you believe UCBJF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UCBJF will underperform the S&P 500 over the long term. You may vote once every thirty days.
